Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Liabilities and Shareholders Equity: 2010-2025

Historic Liabilities and Shareholders Equity for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to $89.6 million.

  • Lineage Cell Therapeutics' Liabilities and Shareholders Equity fell 7.20% to $89.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $405.4 million, marking a year-over-year decrease of 0.85%. This contributed to the annual value of $113.2 million for FY2024, which is 12.08% up from last year.
  • Latest data reveals that Lineage Cell Therapeutics reported Liabilities and Shareholders Equity of $89.6 million as of Q3 2025, which was down 1.28% from $90.8 million recorded in Q2 2025.
  • In the past 5 years, Lineage Cell Therapeutics' Liabilities and Shareholders Equity ranged from a high of $174.5 million in Q4 2021 and a low of $89.6 million during Q3 2025.
  • For the 3-year period, Lineage Cell Therapeutics' Liabilities and Shareholders Equity averaged around $104.1 million, with its median value being $106.2 million (2023).
  • In the last 5 years, Lineage Cell Therapeutics' Liabilities and Shareholders Equity surged by 61.69% in 2021 and then dropped by 29.15% in 2022.
  • Quarterly analysis of 5 years shows Lineage Cell Therapeutics' Liabilities and Shareholders Equity stood at $174.5 million in 2021, then declined by 29.15% to $123.7 million in 2022, then declined by 18.31% to $101.0 million in 2023, then rose by 12.08% to $113.2 million in 2024, then declined by 7.20% to $89.6 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $89.6 million for Q3 2025, versus $90.8 million for Q2 2025 and $111.8 million for Q1 2025.